search
Back to results

Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh (ILEOCLOSE)

Primary Purpose

Loop Ileostomy Closure

Status
Unknown status
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
MESH
NO MESH
Post-operative Imaging
Pre-operative Imaging
Blood Test and C-reactive protein at 4th day
Sponsored by
Hospital Universitari Vall d'Hebron Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Loop Ileostomy Closure focused on measuring Loop ileostomy, Eventration

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients undergoing a loop ileostomy closure

Exclusion Criteria:

  • Patients under 18
  • Pregnancy and Lactation
  • Patients allergic to polyglycolic / trimethylene carbonate
  • Carrier of prosthetic mesh in the ostomy
  • Patients presenting midline hernia.
  • Patients affected by inflammatory bowel disease

Sites / Locations

  • Hospital General Universitario Vall d´HebronRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

MESH

NO MESH

Arm Description

Outcomes

Primary Outcome Measures

Eventration
Measured by clinical checks at 1 - 6 - 12 months and Abdominal tomography 1 year after the surgery.

Secondary Outcome Measures

Occlusive problems
Intestinal occlusion, Anastomotic stenosis, Prolonged ileus(>5days),.... This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently. 1 patient can suffer a prolonged ileus and Anastomotic stenosis and both will be reported.
Iatrogenic problems
Damage to structures such as ureters, bowel loops artery / iliac vein .... This is a Surgical and Clinical measure supported by image if necessary. All the morbidity problems are reported independently.
Impaired healing
Anastomotic leak rate , intestinal fistula , vesical fistula, peritonitis... This is a Clinical measure always supported by image tests. All the morbidity problems are reported independently.
Bleeding problems
Hemoperitoneum, abdominal hematoma,anastomotic bleeding .... This is a Clinical measure supported by image if necessary. All the morbidity problems are reported independently. The amount of blood loss won't be specified
Cardiac complications
acute myocardial infarction, angor pectoris , atrial fibrillation, acute pulmonary edema This is a Clinical measure supported by more specific tests if necessary. All the morbidity problems are reported independently. Cardiologist report will be required for including this items
Nephro-urinary complications
Acute urinary retention, Acute renal failure, cystitis, pyelonephritis ... This is a Clinical measure supported by more specific tests if necessary. All the morbidity problems are reported independently.
Respiratory complications
Pneumonia, Atelectasis, Pulmonary embolism, Respiratory distress syndrome ... This is a Clinical measure always supported by image . All the morbidity problems are reported independently.
Vascular Complications
Deep venous thrombosis, phlebitis, thrombophlebitis, ... This is a Clinical measure supported by more specific test if necessary . All the morbidity problems are reported independently
Gastrointestinal complications
Liver failure, gastrointestinal bleeding, severe malnutrition, ... This is a Clinical measure supported by blood test and further test if necessary All the morbidity problems are reported independently.
Neurological complications
Disorientation, cerebral vascular accident, ... This is a Clinical measure. All the morbidity problems are reported independently. Neurologist report will be required beyond disorientation.
Local infection
Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently
Local complications
Hematoma, seroma, evisceration This is a Clinical measure All the morbidity problems are reported independently
Hospital stay
Hospital stay since surgery is done

Full Information

First Posted
March 18, 2014
Last Updated
April 11, 2017
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02226887
Brief Title
Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh
Acronym
ILEOCLOSE
Official Title
"Prospective Randomized Clinical Trial of Ileostomy Closure Site Hernia and it´s Prophylaxis by Placing an Absorbable Mesh "
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Unknown status
Study Start Date
April 2014 (Actual)
Primary Completion Date
May 2018 (Anticipated)
Study Completion Date
June 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Universitari Vall d'Hebron Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Design Prospective , randomized, parallel phase IV. Objectives Main objective Evaluate the effectiveness of the placement of a resorbable mesh in the prevention of incisional hernia of the abdominal wall at the site of a loop ileostomy when it is "closed " to rebuild the intestinal transit. The effectiveness evaluation is done by tracking with scheduled patient visits for 12 months, assessing the physical examination the presence or absence of an incisional hernia and an abdominal tomography at the end of the 12 months . Secondary objectives Comparison of complications(morbidity and mortality) to assess safety and tolerability of the placement of the mesh described .
Detailed Description
Experimental: Reinforcement with Absorbable Mesh Closure of the ileostomy closure incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore & Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a "sandwich" method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Loop Ileostomy Closure
Keywords
Loop ileostomy, Eventration

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
MESH
Arm Type
Experimental
Arm Title
NO MESH
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
MESH
Other Intervention Name(s)
Mesh : GORE® BIO-A®
Intervention Description
Pre-operative : It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure . Surgical technique: Peristomal incision with electrocautery Release the handle of ileum Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election). Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule. We add the mesh between the edges of the defect during fascia closure. The skin is sutured "purse string" style. Post-Op Hospital discharge after verification of normal digestive transit.
Intervention Type
Procedure
Intervention Name(s)
NO MESH
Other Intervention Name(s)
Protocol Ileostomy closure
Intervention Description
Pre-operative : It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure . Surgical technique: Peristomal incision with electrocautery Release the handle of ileum Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election). Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule. The skin is sutured "purse string" style. Post-Op - Hospital discharge after verification of normal digestive transit
Intervention Type
Radiation
Intervention Name(s)
Post-operative Imaging
Intervention Description
Abdominal Tomography 1 year after ileostomy closure
Intervention Type
Radiation
Intervention Name(s)
Pre-operative Imaging
Intervention Description
Contrast study is used to ensure the integrity of the distal anastomosis
Intervention Type
Other
Intervention Name(s)
Blood Test and C-reactive protein at 4th day
Intervention Description
All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
Primary Outcome Measure Information:
Title
Eventration
Description
Measured by clinical checks at 1 - 6 - 12 months and Abdominal tomography 1 year after the surgery.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Occlusive problems
Description
Intestinal occlusion, Anastomotic stenosis, Prolonged ileus(>5days),.... This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently. 1 patient can suffer a prolonged ileus and Anastomotic stenosis and both will be reported.
Time Frame
30 days after surgery
Title
Iatrogenic problems
Description
Damage to structures such as ureters, bowel loops artery / iliac vein .... This is a Surgical and Clinical measure supported by image if necessary. All the morbidity problems are reported independently.
Time Frame
30 days after surgery
Title
Impaired healing
Description
Anastomotic leak rate , intestinal fistula , vesical fistula, peritonitis... This is a Clinical measure always supported by image tests. All the morbidity problems are reported independently.
Time Frame
30 days after surgery
Title
Bleeding problems
Description
Hemoperitoneum, abdominal hematoma,anastomotic bleeding .... This is a Clinical measure supported by image if necessary. All the morbidity problems are reported independently. The amount of blood loss won't be specified
Time Frame
30 days after surgery
Title
Cardiac complications
Description
acute myocardial infarction, angor pectoris , atrial fibrillation, acute pulmonary edema This is a Clinical measure supported by more specific tests if necessary. All the morbidity problems are reported independently. Cardiologist report will be required for including this items
Time Frame
30 days after surgery
Title
Nephro-urinary complications
Description
Acute urinary retention, Acute renal failure, cystitis, pyelonephritis ... This is a Clinical measure supported by more specific tests if necessary. All the morbidity problems are reported independently.
Time Frame
30 days after surgery
Title
Respiratory complications
Description
Pneumonia, Atelectasis, Pulmonary embolism, Respiratory distress syndrome ... This is a Clinical measure always supported by image . All the morbidity problems are reported independently.
Time Frame
30 days after surgery
Title
Vascular Complications
Description
Deep venous thrombosis, phlebitis, thrombophlebitis, ... This is a Clinical measure supported by more specific test if necessary . All the morbidity problems are reported independently
Time Frame
30 days after surgery
Title
Gastrointestinal complications
Description
Liver failure, gastrointestinal bleeding, severe malnutrition, ... This is a Clinical measure supported by blood test and further test if necessary All the morbidity problems are reported independently.
Time Frame
30 days after surgery
Title
Neurological complications
Description
Disorientation, cerebral vascular accident, ... This is a Clinical measure. All the morbidity problems are reported independently. Neurologist report will be required beyond disorientation.
Time Frame
30 days after surgery
Title
Local infection
Description
Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently
Time Frame
30 days after surgery
Title
Local complications
Description
Hematoma, seroma, evisceration This is a Clinical measure All the morbidity problems are reported independently
Time Frame
30 days after surgery
Title
Hospital stay
Description
Hospital stay since surgery is done
Time Frame
Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing a loop ileostomy closure Exclusion Criteria: Patients under 18 Pregnancy and Lactation Patients allergic to polyglycolic / trimethylene carbonate Carrier of prosthetic mesh in the ostomy Patients presenting midline hernia. Patients affected by inflammatory bowel disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Borja Villanueva Figueredo, MD
Organizational Affiliation
Hospital Universitari Vall d'Hebron Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Francesc Vallribera Valls, MD,PhD
Organizational Affiliation
Hospital Universitari Vall d'Hebron Research Institute
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Manuel Lopez-Cano, MD, PhD
Organizational Affiliation
Hospital Universitari Vall d'Hebron Research Institute
Official's Role
Study Director
Facility Information:
Facility Name
Hospital General Universitario Vall d´Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Borja Villanueva, MD
Phone
+34 629801238
Email
b.villanueva@hotmail.com
First Name & Middle Initial & Last Name & Degree
Borja Villanueva Figueredo, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh

We'll reach out to this number within 24 hrs